Ovarian cancer

Active Ingredient: Melphalan

Indication for Melphalan

Population group: women, only adults (18 years old or older)

Melphalan, at conventional intravenous dosage, is indicated in the treatment of advanced ovarian cancer.

For this indication, competent medicine agencies globally authorize below treatments:

0.2 mg/kg bodyweight/day for 5 days every 4-8 weeks

Route of admnistration

Oral

Defined daily dose

0.2 - 0.2 mg per kg of body weight

Dosage regimen

From 0.2 To 0.2 mg per kg of body weight once every day for 5 day(s)

Detailed description

A typical regimen is 0.2 mg/kg bodyweight/day orally for 5 days. This is repeated every 4-8 weeks, or as soon as the bone marrow has recovered. Melphalan has also been used intravenously in the treatment of ovarian carcinoma.

0.3-1 mg/kg once every 4 weeks

Route of admnistration

Intravenous

Defined daily dose

0.3 - 1 mg per kg of body weight

Dosage regimen

From 0.3 To 1 mg per kg of body weight once every 28 day(s)

Detailed description

When used intravenously as a single agent, a dose of 1 mg/kg body weight (approximately 40 mg/m² body surface area) given at intervals of 4 weeks has often been used.

When combined with other cytotoxic drugs, intravenous doses of between 0.3 and 0.4 mg/kg body weight (12 to 16 mg/m² body surface area) have been used at intervals of 4 to 6 weeks.

12-40 mg/m² body surface area once every 4 weeks

Route of admnistration

Intravenous

Defined daily dose

12 - 40 mg per m² of body surface area (BSA)

Dosage regimen

From 12 To 40 mg per m² of body surface area (BSA) once every 28 day(s)

Detailed description

When used intravenously as a single agent, a dose of 1 mg/kg body weight (approximately 40 mg/m² body surface area) given at intervals of 4 weeks has often been used.

When combined with other cytotoxic drugs, intravenous doses of between 0.3 and 0.4 mg/kg body weight (12 to 16 mg/m² body surface area) have been used at intervals of 4 to 6 weeks.

Active ingredient

Melphalan

Melphalan is a bifunctional alkylating agent. Formation of carbonium intermediates from each of the two bis-2-chloroethyl groups enables alkylation through covalent binding with the 7-nitrogen of guanine on DNA, cross-linking the two DNA strands and thereby preventing cell replication.

Read more about Melphalan

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.